SS-31 (Elamipretide) Description: A mitochondrial-targeting peptide that protects and repairs cellular energy systems, reduces oxidative stress, and improves energy levels
Its mechanisms involve stimulating blood vessel formation, promoting cell migration to injury sites, modulating inflammation, and interacting with nitric oxide pathways crucial for sphincter function
Corts-Albornoz MC, Garca-Guqueta DP, Velez-van-Meerbeke A, Talero-Gutirrez C
Why is BPC-157 popular in peptide research
Phase 1 (Weeks 1 to 2): 0.25 mg subcutaneous injection once daily, morning on empty stomach Phase 2 (Weeks 3 to 6): Maintain 0.25 mg or increase to 0.5 mg based on response and tolerance Phase 3 (Weeks 7 to 8): Continue or begin taper depending on symptom improvement Maintenance: Consider cycling 4 weeks on, 2 weeks off for long-term management Oral dosing requires higher amounts to compensate for bioavailability differences